Mukambro (Ambroxol Hydrochloride)

Ambroxol Hydrochloride, the active ingredient in Mukambro, is a mucolytic presented as an oral dosage form for oral use. It helps to loosen and clear mucus in patients with cough associated with acute respiratory tract infections, chronic bronchitis, and bronchial asthma.

GNH USA supplies Mukambro as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The product complies with EU quality standards and is manufactured under GMP conditions.

Ambroxol Hydrochloride is used as an expectorant/mucolytic to improve mucus clearance in respiratory conditions.

- Acute respiratory tract infection‑related cough: reduces mucus viscosity and facilitates expectoration. - Chronic bronchitis: aids sputum clearance and eases breathing difficulty. - Bronchial asthma: supports mucus removal to improve airway patency.

Ambroxol Hydrochloride may cause a range of adverse reactions, most of which are mild and reversible.

Common Side Effects: - Nausea - Taste disturbance (bitter or metallic taste) - Abdominal discomfort - Skin rash - Dizziness - Headache

Serious or Rare Side Effects: - Anaphylactic or severe allergic reactions - Stevens‑Johnson syndrome or toxic epidermal necrolysis - Hepatic dysfunction (elevated transaminases) - Neutropenia or eosinophilia - Bronchospasm - Severe skin reactions such as drug reaction with eosinophilia and systemic symptoms (DRESS).

When prescribing Ambroxol Hydrochloride, consider the following precautions to ensure safe use.

- Renal impairment: use with caution in severe renal dysfunction. - Hepatic disease: monitor liver function tests during prolonged therapy. - Asthma: observe for possible bronchospasm, especially in severe cases. - Pregnancy and lactation: prescribe only if the expected benefit justifies the potential risk. - Known hypersensitivity: avoid in patients with documented allergy to ambroxol or related compounds. - Store at ambient temperature: keep in the original container, protect from moisture and light.

Ambroxol Hydrochloride can interact with other medicines; awareness of the interaction level guides clinical decisions.

Major Interactions (Avoid): - Anticholinergic agents: may diminish the mucolytic effect of ambroxol. - Cytotoxic chemotherapy agents: potential increase in pulmonary toxicity.

Moderate Interactions (Monitor Closely): - Bronchodilators: additive risk of bronchospasm. - Beta‑blockers: may blunt the therapeutic benefit on airway clearance. - Cough suppressants (e.g., opioid antitussives): may counteract the expectorant action of ambroxol.